Agreement brings innovative CytoSorb therapy to South Africa and sets the stage for future potential expansion

MONMOUTH JUNCTION, N.J., March 16, 2017 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), manufacturer of the CytoSorb® extracorporeal blood purification therapy that reduces excessive levels of inflammatory mediators in critically-ill and cardiac surgery patients, announced today that they have entered into a partnership with Dr. Reddy’s Laboratories Ltd for the South African market.